000			03411nam a22003375i 4500
999			_c402814 _d402814
001			402814
003			ES-MaUEC
005			20240708143459.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			231117s2023 sz | fo |||| 0|eng d
020			_a9783031300653
024	7		_a10.1007/978-3-031-30065-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC270.8 _b2023 EB
245	0	0	_aTargeting the DNA Damage Response for Cancer Therapy _cedited by Timothy A. Yap, Geoffrey I. Shapiro
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Treatment and Research _x2509-8497 ; _v186
505	0		_aEvolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).
520			_aThis book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.
988			_aSpringer_Medicine_2023
650		7	_2embne _9174085 _aCáncer _xTratamiento
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-30065-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2024 _dz _ean _zSI